517 related articles for article (PubMed ID: 34106454)
1. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Travert C; Tomasini P; Greillier L
Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Parikh K; Hendriks LEL; Bironzo P; Remon J
Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
[TBL] [Abstract][Full Text] [Related]
8. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
9. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H; Lanis M; Belcaid Z; Smith KN; Balan A; White JR; Cherry C; Ashok Sivakumar IK; Shao XM; Chan HY; Singh D; Thapa S; Illei PB; Pardoll DM; Karchin R; Velculescu VE; Brahmer JR; Ramalingam SS
Nat Med; 2021 Nov; 27(11):1910-1920. PubMed ID: 34750557
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
13. Pleural mesothelioma (PM) - The status of systemic therapy.
Cui W; Popat S
Cancer Treat Rev; 2021 Nov; 100():102265. PubMed ID: 34399145
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
15. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
[TBL] [Abstract][Full Text] [Related]
16. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
17. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
18. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
19. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
[TBL] [Abstract][Full Text] [Related]
20. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]